AbbVie price target raised to $217 from $211 at Truist

Truist raised the firm’s price target on AbbVie (ABBV) to $217 from $211 and keeps a Buy rating on the shares after its Q4 results. The company’s FY24 results exceeded the management’s recent guidance as AbbVie continues to deliver strong growth into the longer-term, and the firm sees a clear growth trajectory into 2029, the analyst tells investors in a research note.